目的 研究疏血通注射液聯(lián)合羥苯磺酸鈣膠囊治療單純型糖尿病視網(wǎng)膜病變的臨床療效。方法 選取2013年10月-2015年4月在秦皇島市第一醫(yī)院眼科診治的單純型糖尿病視網(wǎng)膜病變患者81例,隨機分為對照組(40例)和治療組(41例)。兩組患者均給予常規(guī)治療,控制血糖水平。對照組患者口服羥苯磺酸鈣膠囊,0.5 g/次,3次/d。治療組患者在對照組的基礎上靜脈滴注疏血通注射液,6.0 mL加入250 mL生理鹽水中,1次/d。兩組患者均連續(xù)治療1個月。觀察兩組患者臨床療效,對比兩組患者治療前后的視力和血液流變學指標變化。結果 治療后,對照組和治療組臨床總有效率分別為75.00%、95.12%,兩組比較差異具有統(tǒng)計學意義(P<0.05)。治療后,治療組患者視力比對照組患者明顯好轉,兩組比較差異具有統(tǒng)計學意義(P<0.05)。治療后,兩組患者血液流變學指標均較同組治療前降低(P<0.05);且治療組降低程度更顯著,兩組比較差異有統(tǒng)計學意義(P<0.05)。兩組間不良反應發(fā)生比較差異無統(tǒng)計學意義。結論 疏血通注射液聯(lián)合羥苯磺酸鈣膠囊能夠有效改善單純型糖尿病視網(wǎng)膜病變患者的臨床癥狀,降低血小板的聚集性和血漿黏度,并且不良反應發(fā)生率低,具有一定的臨床應用推廣價值。

Objective To investigate clinical efficacy of Danshen Injection combined with Entecavir Tablets in treatment of chronic hepatitis B hepatic fibrosis. Methods The patients (136 cases) with chronic hepatitis B hepatic fibrosis in Xining No. 1 People's Hospital from October 2014 to October 2015 were randomly divided into control and treatment groups, and each group had 68 cases. The patients in the control group were po administered with Entecavir Tablets 0.5 mg, once daily. The patients in the treatment group were iv administered with Danshen Injection on the basis of the control group, 30 mL added into 5% Glucose Injection 250 mL, once daily. The patients in two groups were treated for 3 months. After treatment, the efficacy was evaluated, and indexes of liver fibrosis, serum levels of HBV-DNA and TGF-β1 in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 82.4% and 94.1%, respectively, and there were differences between two groups (P < 0.05). After treatment, HA, CIV, PIIINP, and LN in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, serum levels of HBV-DNA and TGF-β1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, serum levels of TGF-β1 in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05), but there were no difference on serum levels of HBV-DNA between two groups. Conclusions Danshen Injection combined with Entecavir Tablets has clinical curative effect in treatment of chronic hepatitis B hepatic fibrosis, and can improve liver fibrosis, and also decrease the serum levels of TGF-β1, which has a certain clinical application value.